A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa

NCT03060629 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2636

Enrollment

INDUSTRY

Sponsor class

Stopped Study was terminated by the sponsor after the last participant completed the Month 24 visit as the pre-specified criteria to continue the study were not met.

Conditions

HIV-1

Interventions

BIOLOGICAL: Ad26.Mos4.HIV
BIOLOGICAL: Clade C gp140
BIOLOGICAL: Placebo

Sponsor

Janssen Vaccines & Prevention B.V.